The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Oxidative Damage in Huntington's Disease Pathogenesis
Abstract
Huntington's disease (HD) is a devastating neurodegenerative disorder characterized by the progressive development of involuntary choreiform movements, cognitive impairment, neuropsychiatric symptoms, and premature death. These phenotypes reflect neuronal dysfunction and ultimately death in selected brain regions, the striatum and cerebral cortex being principal targets. The genetic mutation responsible for the HD phenotype is known, and its protein product, mutant huntingtin (mhtt), identified. HD is one of several "triplet repeat" diseases, in which abnormal expansions in trinucleotide repeat domains lead to elongated polyglutamine stretches in the affected gene's protein product. Mutant htt-mediated toxicity in the brain disrupts a number of vital cellular processes in the course of disease progression, including energy metabolism, gene transcription, clathrin-dependent endocytosis, intraneuronal trafficking, and postsynaptic signaling, but the crucial initiation mechanism induced by mhtt is still unclear. A large body of evidence, however, supports an early and critical involvement of defects in mitochondrial function and CNS energy metabolism in the disease trigger. Thus, downstream death-effector mechanisms, including excitotoxicity, apoptosis, and oxidative damage, have been implicated in the mechanism of selective neuronal damage in HD. Here we review the current evidence supporting a role for oxidative damage in the etiology of neuronal damage and degeneration in HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
The functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase
Ischiropoulos, H., Zhu, L., Chen, J., Tsai, M., Martin, J. C., Smith, C. D., & Beckman, J. S. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90431-u · Cited by 1,495
Ishii, T., Itoh, K., Takahashi, S., Sato, H., Yanagawa, T., Katoh, Y., Bannai, S., & Yamamoto, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.21.16023 · Cited by 1,460
G. Vonsattel, J. P., & DiFiglia, M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199805000-00001 · Cited by 1,306
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,286
Self-citationKlivenyi, P., Andreassen, O. A., Ferrante, R. J., Dedeoglu, A., Mueller, G., Lancelot, E., Bogdanov, M., Andersen, J. K., Jiang, D., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00001.2000 · Cited by 1,111
Self-citationSteffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986
Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Self-citationLee, J.-M., Calkins, M. J., Chan, K., Kan, Y. W., & Johnson, J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211558200 · Cited by 786
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Inactivation of the Mouse Huntington's Disease Gene Homolog Hdh
Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J.-P., Gusella, J. F., Joyner, A. L., et al. (1995) · Science · doi:10.1126/science.7618107 · Cited by 723
Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease
Dunah, A. W., Jeong, H., Griffin, A., Kim, Y.-M., Standaert, D. G., Hersch, S. M., Mouradian, M. M., Young, A. B., Tanese, N., & Krainc, D. (2002) · Science · doi:10.1126/science.1072613 · Cited by 708
HEYES, M. P., SAITO, K., CROWLEY, J. S., DAVIS, L. E., DEMITRACK, M. A., DER, M., DILLING, L. A., ELIA, J., KRUESI, M. J. P., LACKNER, A., et al. (1992) · Brain · doi:10.1093/brain/115.5.1249 · Cited by 680
Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models
Portera-Cailliau, C., Hedreen, J., Price, D., & Koliatsos, V. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-03775.1995 · Cited by 607
Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., Hayden, M. R., & Raymond, L. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00615-3 · Cited by 595
Sawa, A., Wiegand, G. W., Cooper, J., Margolis, R. L., Sharp, A. H., Lawler, J. F., Greenamyre, J. T., Snyder, S. H., & Ross, C. A. (1999) · Nature Medicine · doi:10.1038/13518 · Cited by 552
Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain
Sapp, E., Kegel, K. B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P. G., Vonsattel, J. P., & Difiglia, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.2.161 · Cited by 540
The hunt for huntingtin function: interaction partners tell many different stories
Harjes, P., & Wanker, E. E. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00168-3 · Cited by 539
Kang, M.-I., Kobayashi, A., Wakabayashi, N., Kim, S.-G., & Yamamoto, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308347100 · Cited by 534
Transcriptional abnormalities in Huntington disease
Sugars, K. L., & Rubinsztein, D. C. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00074-x · Cited by 529
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro
Trushina, E., Dyer, R. B., Badger, J. D., Ure, D., Eide, L., Tran, D. D., Vrieze, B. T., Legendre-Guillemin, V., McPherson, P. S., Mandavilli, B. S., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.8195-8209.2004 · Cited by 520
Choo, Y. S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh162 · Cited by 515
Oxidative stress in Huntington’s disease
Browne, S. E., Ferrante, R. J., & Beal, M. F. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00216.x · Cited by 508
Self-citationChronic quinolinic acid lesions in rats closely resemble Huntington's disease
Beal, M., Ferrante, R., Swartz, K., & Kowall, N. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-06-01649.1991 · Cited by 499
Self-citationBolaños, J. P., Heales, S. J. R., Land, J. M., & Clark, J. B. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64051965.x · Cited by 492
3-Nitropropionic Acid - Exogenous Animal Neurotoxin and Possible Human Striatal Toxin
Ludolph, A. C., He, F., Spencer, P. S., Hammerstad, J., & Sabri, M. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100032212 · Cited by 485
Brouillet, E., Hantraye, P., Ferrante, R. J., Dolan, R., Leroy-Willig, A., Kowall, N. W., & Beal, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7105 · Cited by 485
Self-citationNeuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease
Matthews, R. T., Yang, L., Jenkins, B. G., Ferrante, R. J., Rosen, B. R., Kaddurah-Daouk, R., & Beal, M. F. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00156.1998 · Cited by 430
Self-citationLunkes, A., Lindenberg, K. S., Ben-Haı̈em, L., Weber, C., Devys, D., Landwehrmeyer, G. B., Mandel, J.-L., & Trottier, Y. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00602-0 · Cited by 416
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Self-citationCaspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease
Wellington, C. L., Ellerby, L. M., Gutekunst, C.-A., Rogers, D., Warby, S., Graham, R. K., Loubser, O., van Raamsdonk, J., Singaraja, R., Yang, Y.-Z., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07862.2002 · Cited by 399
NMDA Receptor Losses in Putamen from Patients with Huntington's Disease
Young, A. B., Greenamyre, J. T., Hollingsworth, Z., Albin, R., D'Amato, C., Shoulson, I., & Penney, J. B. (1988) · Science · doi:10.1126/science.2841762 · Cited by 395
Lipofuscin: Mechanisms of formation and increase with age
TERMAN, A., & BRUNK, U. T. (1998) · APMIS · doi:10.1111/j.1699-0463.1998.tb01346.x · Cited by 387
Brouillet, E., Jacquard, C., Bizat, N., & Blum, D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03515.x · Cited by 364
Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
Tabrizi, S. J., Workman, J., Hart, P. E., Mangiarini, L., Mahal, A., Bates, G., Cooper, J. M., & Schapira, A. H. V. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<80::aid-ana13>3.0.co;2-k · Cited by 351
Birch, P. J., Grossman, C. J., & Hayes, A. G. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90367-6 · Cited by 318
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313
Self-citationBeal, M. F., Matson, W. R., Swartz, K. J., Gamache, P. H., & Bird, E. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb03143.x · Cited by 311
Self-citationTryptophan metabolism and oxidative stress in patients with Huntington's disease
Stoy, N., Mackay, G. M., Forrest, C. M., Christofides, J., Egerton, M., Stone, T. W., & Darlington, L. G. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03070.x · Cited by 310
Kynurenines in the CNS: from endogenous obscurity to therapeutic importance
Stone, T. W. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00032-0 · Cited by 306
Sun, Y., Savanenin, A., Reddy, P. H., & Liu, Y. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103501200 · Cited by 297
HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism
Seong, I. S., Ivanova, E., Lee, J.-M., Choo, Y. S., Fossale, E., Anderson, M., Gusella, J. F., Laramie, J. M., Myers, R. H., Lesort, M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi319 · Cited by 294
Neurons Containing NADPH-Diaphorase Are Selectively Resistant to Quinolinate Toxicity
Koh, J.-Y., Peters, S., & Choi, D. W. (1986) · Science · doi:10.1126/science.2875522 · Cited by 287
Weight loss in early stage of Huntington’s disease
Djoussé, L., Knowlton, B., Cupples, L. A., Marder, K., Shoulson, I., & Myers, R. H. (2002) · Neurology · doi:10.1212/01.wnl.0000031791.10922.cf · Cited by 285
Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo
Schulz, J., Matthews, R., Jenkins, B., Ferrante, R., Siwek, D., Henshaw, D., Cipolloni, P., Mecocci, P., Kowall, N., & Rosen, B. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-12-08419.1995 · Cited by 281
Gines, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg046 · Cited by 276
NMDA receptor function in mouse models of Huntington disease
Cepeda, C., Ariano, M. A., Calvert, C. R., Flores‐Hernández, J., Chandler, S. H., Leavitt, B. R., Hayden, M. R., & Levine, M. S. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1244 · Cited by 274
Shih, A. Y., Imbeault, S., Barakauskas, V., Erb, H., Jiang, L., Li, P., & Murphy, T. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414635200 · Cited by 273
Gonzalez-Zulueta, M., Ensz, L. M., Mukhina, G., Lebovitz, R. M., Zwacka, R. M., Engelhardt, J. F., Oberley, L. W., Dawson, V. L., & Dawson, T. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-02040.1998 · Cited by 265
Milakovic, T., & Johnson, G. V. W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504749200 · Cited by 261
Velier, J., Kim, M., Schwarz, C., Kim, T. W., Sapp, E., Chase, K., Aronin, N., & DiFiglia, M. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6832 · Cited by 258
Lodi, R., Schapira, A. H. V., Manners, D., Styles, P., Wood, N. W., Taylor, D. J., & Warner, T. T. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1<72::aid-ana11>3.0.co;2-i · Cited by 254
Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease
Bogdanov, M. B., Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., & Beal, M. F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00689.x · Cited by 248
Self-citationCalkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., & Johnson, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408487101 · Cited by 247
The Energetics of Huntington's Disease
Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240
Self-citationLandwehrmeyer, G. B., McNeil, S. M., Dure, L. S., Ge, P., Aizawa, H., Huang, Q., Ambrose, C. M., Duyao, M. P., Bird, E. D., Bonilla, E., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410370213 · Cited by 222
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex
Flint Beal, M., Matson, W. R., Storey, E., Milbury, P., Ryan, E. A., Ogawa, T., & Bird, E. D. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90191-m · Cited by 218
CORTICAL AND SUBCORTICAL GLUCOSE CONSUMPTION MEASURED BY PET IN PATIENTS WITH HUNTINGTON'S DISEASE
KUWERT, T., LANGE, H. W., LANGEN, K.-J., HERZOG, H., AULICH, A., & FEINENDEGEN, L. E. (1990) · Brain · doi:10.1093/brain/113.5.1405 · Cited by 217
Brouillet, E., Guyot, M., Mittoux, V., Altairac, S., Condé, F., Palfi, S., & Hantraye, P. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70020794.x · Cited by 210
Greene, J. G., Porter, R. H. P., Eller, R. V., & Greenamyre, J. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03634.x · Cited by 208
Celastrol protects against MPTP‐ and 3‐nitropropionic acid‐induced neurotoxicity
Cleren, C., Calingasan, N. Y., Chen, J., & Beal, M. F. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03253.x · Cited by 207
Self-citationHomozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course
Squitieri, F. (2003) · Brain · doi:10.1093/brain/awg077 · Cited by 203
Deadly Conversations: Nuclear-Mitochondrial Cross-Talk
Dawson, V. L., & Dawson, T. M. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041755.22613.8d · Cited by 194
Fusco, F. R., Chen, Q., Lamoreaux, W. J., Figueredo-Cardenas, G., Jiao, Y., Coffman, J. A., Surmeier, D. J., Honig, M. G., Carlock, L. R., & Reiner, A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-04-01189.1999 · Cited by 191
Proteomic Analysis of Protein Expression and Oxidative Modification in R6/2 Transgenic Mice
Perluigi, M., Poon, H. F., Maragos, W., Pierce, W. M., Klein, J. B., Calabrese, V., Cini, C., De Marco, C., & Butterfield, D. A. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500090-mcp200 · Cited by 186
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease
Saft, C., Zange, J., Andrich, J., Müller, K., Lindenberg, K., Landwehrmeyer, B., Vorgerd, M., Kraus, P. H., Przuntek, H., & Schöls, L. (2005) · Movement Disorders · doi:10.1002/mds.20373 · Cited by 183
Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin
Chen, N., Luo, T., Wellington, C., Metzler, M., McCutcheon, K., Hayden, M. R., & Raymond, L. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721890.x · Cited by 180
Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
Feigin, A., Leenders, K. L., Moeller, J. R., Missimer, J. H., Kuenig, G., Spetsieris, P. G., Antonini, A., & Eidelberg, D. (2001) · PubMed · Cited by 178
Huntingtin's Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing
Rigamonti, D., Sipione, S., Goffredo, D., Zuccato, C., Fossale, E., & Cattaneo, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100044200 · Cited by 174
Waelter, S. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.17.1807 · Cited by 169
Wild-Type Huntingtin Plays a Role in Brain Development and Neuronal Survival
Reiner, A., Dragatsis, I., Zeitlin, S., & Goldowitz, D. (2003) · Molecular Neurobiology · doi:10.1385/mn:28:3:259 · Cited by 165
Hansson, O., Guatteo, E., Mercuri, N. B., Bernardi, G., Li, X., Castilho, R. F., & Brundin, P. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01767.x · Cited by 165
Beal, M. F., Ferrante, R. J., Henshaw, R., Matthews, R. T., Chan, P. H., Kowall, N. W., Epstein, C. J., & Schulz, J. B. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65020919.x · Cited by 162
Self-citationModregger, J., Prospero, N. D., Charles, V., Tagle, D., & Plomann, M. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.21.2547 · Cited by 161
Schulz, J. B., Matthews, R. T., Henshaw, D. R., & Beal, M. F. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00527-7 · Cited by 156
Self-citationIncreased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease
Pearson, S. J., & Reynolds, G. P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90749-w · Cited by 155
Neuropathologic Correlates of Apathy in Alzheimer’s Disease
Marshall, G. A., Fairbanks, L. A., Tekin, S., Vinters, H. V., & Cummings, J. L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000090674 · Cited by 149
INVOLVEMENT OF OXIDATIVE STRESS IN 3-NITROPROPIONIC ACID NEUROTOXICITY
Schulz, J. B., Henshaw, D. R., MacGarvey, U. M., & Beal, M. F. (1996) · Neurochemistry International · doi:10.1016/0197-0186(95)00122-0 · Cited by 144
Self-citation3‐Nitropropionic Acid Toxicity in the Striatum
Wüllner, U., Young, A. B., Penney, J. B., et al. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63051772.x · Cited by 137
Pérez‐Severiano, F., Ríos, C., & Segovia, J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02082-5 · Cited by 136
Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease
Djoussé, L., Knowlton, B., Hayden, M., Almqvist, E. W., Brinkman, R., Ross, C., Margolis, R., Rosenblatt, A., Durr, A., Dode, C., et al. (2003) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.20190 · Cited by 135
Kehoe, P. G., Krawczak, M., Harper, P. S., Owen, M. J., & Jones, A. L. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.2.108 · Cited by 134
Relationship between trinucliotide repeats and neuropathological changes in Huntington's diease
Furtado, S., Suchowersky, O., Rewcastle, N. B., Graham, L. M., Klimek, M. L., & Garber, A. T. (1996) · Annals of Neurology · doi:10.1002/ana.410390120 · Cited by 133
Transgenic models of Huntington's disease.
Sathasivam, K., Hobbs, C., Mangiarini, L., Mahal, A., Turmaine, M., Doherty, P., Davies, S., & Bates, G. (1999) · Human Molecular Genetics · doi:10.1098/rstb.1999.0447 · Cited by 133
Kim, G. W., Gasche, Y., Grzeschik, S. M., Copin, J., Maier, C. M., & Chan, P. H. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-25-08733.2003 · Cited by 131
Calabresi, P., Centonze, D., Pisani, A., Sancesario, G., Gubellini, P., Marfia, G. A., & Bernardi, G. (1998) · Annals of Neurology · doi:10.1002/ana.410430506 · Cited by 131
Jauch, D., Urbańska, E. M., Guidetti, P., Bird, E. D., Vonsattel, J., Whetsell, W. O., & Schwarcz, R. M. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)00280-2 · Cited by 127
Mutant Huntingtin: Nuclear translocation and cytotoxicity mediated by GAPDH
Bae, B.-I., Hara, M. R., Cascio, M. B., Wellington, C. L., Hayden, M. R., Ross, C. A., Ha, H. C., Li, X.-J., Snyder, S. H., & Sawa, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511316103 · Cited by 123
Andreassen, O. A., Ferrante, R. J., Dedeoglu, A., Albers, D. W., Klivènyi, P., Carlson, E. J., Epstein, C. J., & Beal, M. F. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7525 · Cited by 122
Self-citationFontaine, M. A. L., Geddes, J. W., Banks, A., & Butterfield, D. A. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751709.x · Cited by 118
Neurochemistry and toxin models in Huntingtonʼs disease
Beal, M. F. (1994) · Current Opinion in Neurology · doi:10.1097/00019052-199412000-00012 · Cited by 118
Self-citationKim, G. W., Copin, J., 川瀬, 誠., Chen, S. F., Sato, S., Gobbel, G. T., & Chan, P. H. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200001000-00016 · Cited by 116
Lipoic acid improves survival in transgenic mouse models of Huntington's disease
Andreassen, O. A., Ferrante, R. J., Dedeoglu, A., & Beal, M. F. (2001) · Neuroreport · doi:10.1097/00001756-200110290-00044 · Cited by 115
Self-citationNR2A and NR2B receptor gene variations modify age at onset in Huntington disease
Arning, L., Kraus, P. H., Valentin, S., Carsten Saft, C., Andrich, J., & Epplen, J. T. (2004) · Neurogenetics · doi:10.1007/s10048-004-0198-8 · Cited by 113
Brain Quinolinic Acid in Huntington's Disease
Reynolds, G. P., Pearson, S. J., Halket, J. M., & Sandier, M. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb02503.x · Cited by 109
Goebel, H. H., Heipertz, R., Scholz, W. W., Iqbal, K., & Tellez-Nagel, I. (1978) · Neurology · doi:10.1212/wnl.28.1.23 · Cited by 108
MacDonald, M. E., Ginés, S., Gusella, J. F., & Wheeler, V. C. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:7 · Cited by 104
Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model
Guidetti, P., Reddy, P. H., Tagle, D. A., & Schwarcz, R. M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00956-3 · Cited by 97
Butterworth, N. J., Williams, L. C., Bullock, J. Y., Love, D. R., Faull, R. L. M., & Dragunow, M. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00129-8 · Cited by 96
Squitieri, F., Cannella, M., Sgarbi, G., Maglione, V., Falleni, A., Lenzi, P., Baracca, A., Cislaghi, G., Carsten Saft, C., Ragona, G., et al. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.010 · Cited by 96
Ruan, Q., Lesort, M., MacDonald, M. E., & Johnson, G. V. W. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh082 · Cited by 96
Panov, A. V., Lund, S. A., & Greenamyre, J. T. (2005) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-3454-9 · Cited by 95
Nazé, P., Vuillaume, I., Destée, A., Pasquier, F., & Sablonnière, B. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00231-8 · Cited by 95
Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease
Bogdanov, M. B., Ferrante, R. J., Kuemmerle, S., Klivènyi, P., & Beal, M. F. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062642.x · Cited by 88
Self-citationClinical Aspects of CAG Repeat Diseases
Nance, M. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb00892.x · Cited by 88
HAP1 and intracellular trafficking
Li, X., & Li, S.-H. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.001 · Cited by 87
Tadros, M. G., Khalifa, A. E., Abdel‐Naim, A. B., & Arafa, H. M. M. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.10.018 · Cited by 79
de la Cruz, V. P., González‐Cortés, C., Galván‐Arzate, S., Medina‐Campos, O. N., Pérez‐Severiano, F., Ali, S. F., Pedraza‐Chaverrí, J., & Santamaría, A. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.06.027 · Cited by 77
Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16
Djouss�, L., Knowlton, B. A., Hayden, M. R., Brinkman, R. R., Ross, C. A., Margolis, R. L., Rosenblatt, A., Dürr, A., Dodé, C., Morrison, P. J., et al. (2004) · Neurogenetics · doi:10.1007/s10048-004-0175-2 · Cited by 77
Neuroprotective effects of creatine administration against NMDA and malonate toxicity
Malcon, C., Kaddurah-Daouk, R. F., & Beal, M. F. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02038-2 · Cited by 76
Self-citationThe use of transgenic and knock-in mice to study Huntington’s disease
Hickey, M. A., & Chesselet, M.-F. (2003) · Cytogenetic and Genome Research · doi:10.1159/000072863 · Cited by 69
Calmodulin Regulates Transglutaminase 2 Cross-Linking of Huntingtin
Zainelli, G. M., Ross, C. A., Troncoso, J. C., Fitzgerald, J. K., & Muma, N. A. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4424-03.2004 · Cited by 63
Ryu, J. K., Kim, S. U., & McLarnon, J. G. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.006 · Cited by 62
Klivènyi, P., Ferrante, R. J., Gardian, G., Browne, S. E., Chabrier, P., & Beal, M. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.t01-1-01868.x · Cited by 62
Self-citationKim, G. W., & Chan, P. H. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200207000-00005 · Cited by 59
Kim, G. W., & Chan, P. H. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0327 · Cited by 58
Quinolinic acid reduces the antioxidant defenses in cerebral cortex of young rats
Leipnitz, G., Schumacher, C., Scussiato, K., Dalcin, K. B., Wannmacher, C. M. D., Wyse, Â. T. D. S., Dutra‐Filho, C. S., Wajner, M., & Latini, A. (2005) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.08.004 · Cited by 58
Increase in Kynurenic Acid in Huntington's Disease Motor Cortex
Connick, J. H., Carla�, V., Moroni, F., & Stone, T. W. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb02552.x · Cited by 58
Meade, C. A., Figueredo-Cardenas, G., Fusco, F. R., Nowak, T. S., Pulsinelli, W. A., & Reiner, A. J. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7530 · Cited by 54
Mechanisms of neuronal cell death in Huntington’s disease
Sawa, A., Tomoda, T., & Bae, B.-I. (2003) · Cytogenetic and Genome Research · doi:10.1159/000072864 · Cited by 51
Dedeoglu, A., Ferrante, R. J., Andreassen, O. A., DILLMANN, W. H., & Beal, M. F. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7933 · Cited by 50
Self-citationA novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities
Yang, L., Calingasan, N. Y., Chen, J., Ley, J. J., Becker, D. A., & Beal, M. F. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.012 · Cited by 48
Self-citationSawa, A., Nagata, E., Sutcliffe, S., Dulloor, P., Cascio, M. B., Ozeki, Y., Roy, S., Ross, C. A., & Snyder, S. H. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.02.013 · Cited by 45
Puranam, K. L., Wu, G., Strittmatter, W. J., & Burke, J. R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.007 · Cited by 44
Choo, Y. S., Mao, Z., Johnson, G. V. W., & Lesort, M. J. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.05.065 · Cited by 42
Accumulation of Cardiac Lipofuscin Depends on Metabolic Rate of Mammals
Nakano, M., & Gotoh, S. (1992) · Journal of Gerontology · doi:10.1093/geronj/47.4.b126 · Cited by 39
Feany, M. Β., & Spada, A. R. L. (2003) · Neuron · doi:10.1016/s0896-6273(03)00600-7 · Cited by 37
Protective effects of S-nitrosoglutathione against neurotoxicity of 3-nitropropionic acid in rat
Ju, T., Yang, Y.-T. C., & Yang, D. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.03.028 · Cited by 36
Effects of striatal excitotoxicity on Huntingtin-like immunoreactivity
Tatter, S. B., Galpern, W. R., Hoogeveen, A. T., et al. (1995) · Neuroreport · doi:10.1097/00001756-199505300-00013 · Cited by 31
Huntingtin Fragments that Aggregate Go Their Separate Ways
DiFiglia, M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00609-3 · Cited by 28
Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder
Dean, B., Scarr, E., & McLeod, M. C. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.04.005 · Cited by 27
Id, M., Jovanović, Čolić, M. J., Mihajlovic, R., Mićić, D., Selaković, V., Ninković, M., Maličević, Ž., Rusić-Stojiljković, M., & Jovicic, A. (2001) · PubMed · Cited by 25
Diguet, E., Fernagut, P., Normand, E., et al. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.010 · Cited by 19
Toxin-induced mitochondrial dysfunction
Browne, S. E., & Beal, M. F. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53010-5 · Cited by 18
Self-citationIncreased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1
(2006) · PubMed
Cited by
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543
Oxidative Stress and Neurotoxicity
Sayre, L. M., Perry, G., & Smith, M. A. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700210j · Cited by 867
Role of ROS and Nutritional Antioxidants in Human Diseases
Liu, Z., Ren, Z., Zhang, J., Chuang, C.-C., Kandaswamy, E., Zhou, T., & Zuo, L. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00477 · Cited by 860
Buendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., & León, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 678
Apoptosis and Oxidative Stress in Neurodegenerative Diseases
Radi, E., Formichi, P., Battisti, C., & Federico, A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132738 · Cited by 630
Metadata
- Authors
- Browne, S. E., & Beal, M. F.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2006-11
- Volume
- 8
- Issue
- 11-12
- Pages
- 2061-2073
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W1978138384
- Cited by
- 310
- References
- 144
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.